Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Bitterman, Danielle SWinter, Kathryn A
Hong, Theodore S
Fuchs, Charles S
Regine, William F
Abrams, Ross A
Safran, Howard
Hoffman, John P
Benson, Al B
Kasunic, Timothy
Mulcahy, Mary
Strauss, James F
DiPetrillo, Thomas
Stella, Philip J
Chen, Yuhchyau
Plastaras, John P
Crane, Christopher H
Date
2020-08-26Journal
International Journal of Radiation Oncology, Biology, PhysicsPublisher
Elsevier Inc.Type
Article
Metadata
Show full item recordAbstract
Purpose: Diabetes mellitus (DM) has been proposed to be tumorigenic; however, prior studies of the association between DM and survival are conflicting. The goal of this ancillary analysis of RTOG 9704, a randomized controlled trial of adjuvant chemotherapy in pancreatic cancer, was to determine the prognostic effects of DM and insulin use on survival. Methods and Materials: Eligible patients from RTOG 9704 with available data on DM and insulin use were included. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and variable levels were compared using log-rank test. Cox proportional hazards models were created to assess the associations among DM, insulin use, and body mass index phenotypes on outcomes. Results: Of 538 patients enrolled from 1998 to 2002, 238 patients were eligible with analyzable DM and insulin use data. Overall 34% of patients had DM and 66% did not. Of patients with DM, 64% had insulin-dependent DM, and 36% had non–insulin-dependent DM. On univariable analysis, neither DM nor insulin dependence were associated with OS or DFS (P >.05 for all). On multivariable analysis, neither DM, insulin use, nor body mass index were independently associated with OS or DFS. Nonwhite race (hazard ratio [HR], 2.18; 95% confidence interval [CI], 1.35-3.50; P =.0014), nodal involvement (HR, 1.74; 95% CI, 1.24-2.45; P =.0015), and carbohydrate antigen 19-9 (CA19-9) ≥90 U/mL (HR, 3.61; 95% CI, 2.32-5.63; P <.001) were associated with decreased OS. Nonwhite race (HR, 1.67; 95% CI, 1.05-2.63; P =.029) and CA19-9 ≥90 U/mL (HR, 2.86; 95% CI, 1.85-4.40; P <.001) were associated with decreased DFS. Conclusions: DM and insulin use were not associated with OS or DFS in patients with pancreatic cancer in this study. Race, nodal involvement, and increased CA19-9 were significant predictors of outcomes. These data might apply to the more modern use of neoadjuvant therapies for potentially resectable pancreatic cancer.Rights/Terms
Copyright © 2020 Elsevier Inc. All rights reserved.Identifier to cite or link to this item
http://hdl.handle.net/10713/14336ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2020.08.042
Scopus Count
Collections
Related articles
- Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.
- Authors: Reyngold M, Winter KA, Regine WF, Abrams RA, Safran H, Hoffman JP, Mowat RB, Hayes JP, Kessel IL, DiPetrillo T, Narayan S, Chen Y, Ben-Josef E, Delouya G, Suh JH, Meyer J, Haddock MG, Feldman M, Gaur R, Yost K, Peterson RA, Sherr DL, Moughan J, Crane CH
- Issue date: 2020 Mar
- The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704.
- Authors: Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG
- Issue date: 2011 Dec 1
- Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931.
- Authors: Lu DJ, Luu M, Gay C, Nguyen AT, Anderson EM, Bernier J, Cooper JS, Harari PM, Torres-Saavedra PA, Le QT, Chen MM, Clair JM, Ho AS, Zumsteg ZS
- Issue date: 2022 Jul 15
- Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas.
- Authors: Ben-Josef E, George A, Regine WF, Abrams R, Morgan M, Thomas D, Schaefer PL, DiPetrillo TA, Fromm M, Small W Jr, Narayan S, Winter K, Griffith KA, Guha C, Williams TM
- Issue date: 2015 Dec 15
- The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis.
- Authors: Ma J, Wang J, Ge L, Long B, Zhang J
- Issue date: 2019 Oct